Real-world Effectiveness, Safety, and Immunogenicity of Chikungunya Vaccination During an Epidemic Period: an Ambispective Study in Réunion Island and French Guiana.
In the context of the ongoing chikungunya epidemic in Réunion Island and the anticipated epidemic in French Guiana, the investigators propose an ambispective study to evaluate the real-world effectiveness, safety, and immunogenicity of the recommended vaccines, IXCHIQ® and VIMKUNYA®, as defined by the French National Authority for Health (HAS).
⁃ Retrospective study VIMKUNYA or IXCHIQ
• Adult (Aged 18 or above)
• Adult (Aged 18 or above) eligible for anti-chikungunya vaccination according to French High Health Authority (HAS)
⁃ Prospective study
• VIMKUNYA: Adult (Aged 18 or above) eligible for anti-chikungunya vaccination according to French High Health Authority (HAS)
• IXCHIQ: Adult (Aged 18 -64) eligible for anti-chikungunya vaccination according to French High Health Authority (HAS) Eligibility Criteria common to both groups
• Agreeing to participate in study
• Beneficiary of French social security coverage
• Signature of informed consent form